Prosus, in a report, disclosed that Byju's and Pharmeasy are 'large underperformers' affecting its IRR. Prosus has slashed the valuation of Byju's to 'sub-$3 billion,' marking it down from India's most valuable startup.
🚨🚨 #JustIn | Prosus on @BYJUS valuation https://t.co/dINuiRSu3V
Prosus slashes Indian edtech giant Byju’s valuation to ‘sub-$3 billion’: https://t.co/foc1BwAPBq by TechCrunch #infosec #cybersecurity #technology #news
Prosus slashes Indian edtech giant Byju's valuation to 'sub-$3 billion' https://t.co/PGIFhBh8AP by @refsrc
Prosus has marked down the valuation of Byju's, India's most valuable startup, to "sub-$3 billion."
Byju's, Pharmeasy among "large underperformers" impacting IRR, Prosus discloses in a report. https://t.co/kVAcEER9dP